Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Open Label Single Arm Study to Assess the Implementation of Home Based Daratumumab Administration in Patients Being Treated for Multiple Myeloma

Adam F. Binder, Ubaldo Martinez Outschoorn, Carol Gung, Alexandra Cohen, Mallika Saini, Onder Alpdogan, Pierluigi Porcu, Kristin L Rising

Blood (2024) 144 (Supplement 1): 7596.

https://doi.org/10.1182/blood-2024-206031

Published: 2024

Journal Articles

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Blood (2024) 144 (Supplement 1): 3381.1.

https://doi.org/10.1182/blood-2024-199411

Published: 2024

Journal Articles

Outcome of Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide - a Single Center Experience

Yang Yang, Adam F. Binder, Xia Bi, Joanne Filicko-O'Hara, William O'Hara, Neal Flomenberg, Dolores A. Grosso, John L. Wagner, Arpona Dev Nath, Sikemi Ibikunle, Eliabeth Spitz, Usama Gergis

Blood (2023) 142 (Supplement 1): 7110.

https://doi.org/10.1182/blood-2023-173576

Published: 2023

Journal Articles

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Gina Keiffer, Sara E. Meyer, Christine Eischen, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner, Neil Palmisiano

Blood (2023) 142 (Supplement 1): 1551.

https://doi.org/10.1182/blood-2023-186765

Published: 2023

Journal Articles

Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Blood (2023) 142 (Supplement 1): 3028.

https://doi.org/10.1182/blood-2023-187847

Published: 2023

Journal Articles

A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Gina Keiffer, Bruno Calabretta, Alexander Mazo, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner

Blood (2023) 142 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2023-186671

Published: 2023

Journal Articles

Perceptions of a Home Blood Transfusion Program Among Patients with Hematologic Malignancies Who Are Newly Diagnosed As Compared to Those with Relapsed/Refractory Disease

Riyana Doshi, Karla Martin Gonzalez, Alavi Hossain, Alexzandra T Gentsch, Angelica Vivero, Lindsay Wilde, Kristin L Rising, Adam F. Binder

Blood (2023) 142 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2023-185301

Published: 2023

Journal Articles

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Jonathan Pan, MD, Sushil Ghimire, MD, Molly Halloran, MD, Alexander Xu, BA, Tingting Zhan, PhD, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc, Adam F. Binder, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-143146

Published: 2020

Journal Articles

Assessment of the Diagnostic Accuracy of Core Needle Biopsies in the Diagnosis of Lymphoma

Xiangyun Ye, Catherine Tucker, MD, Christopher Gardner, Austin Redilla, Guldeep Uppal, MD, Adam F. Binder, MD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-143306

Published: 2020

Journal Articles

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Lindsay Wilde, MD, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, Onder Alpdogan, MD, Margaret Kasner, MDMSc, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Dolores Grosso, DNP, CRNP, Michael Millenson, Amy R. MacKenzie, MD, Allison Zibelli, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Usama Gergis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140719

Published: 2020

Journal Articles

Retrospective Analysis of the Relationship between Time to Anti-Resorptive Therapy and Incidence of Skeletal Related Events in Patients with Multiple Myeloma

Kelly Hughes, Abdullateef O Abdulkareem, MD MPH, Niketa Raj, Adam Barsouk, Tingting Zhan, PhD, Adam F. Binder, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-143340

Published: 2020

Journal Articles

Vaccination Response after Autologous Stem Cell Transplantation

Onder Alpdogan, MD, Jennifer Hong, MD, Thomas R. Klumpp, MD, Abdullateef O Abdulkareem, MD MPH, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Dolores Grosso, DNP, CRNP, Margaret Kasner, MDMSc, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Lindsay Wilde, MD, Pierluigi Porcu, MD, Usama Gergis, MD, John L. Wagner, MD, Neal Flomenberg, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141269

Published: 2020

Journal Articles

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Mateo Mejia Saldarriaga, MD, Amir Steinberg, MD, Adam F. Binder, MD

Blood (2018) 132 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2018-99-112652

Published: 2018

Journal Articles

Autologous Transplantation Is Associated with Better Outcomes Compared to Chemotherapy Alone in a Minority-Rich Non-High-Risk Acute Myeloid Leukemia Cohort

Diego Adrianzen Herrera, MD, Nilupa Gaspe Mudiyanselage, MD, Pramod Gaudel, MD, Anjali Budhathoki, MD, Karine Darbinyan, MD, Aditi Shastri, MD, Murali Janakiram, MD, Adam F. Binder, MD, Noah Kornblum, MD, Olga Derman, Kira Gritsman, MD PhD, Ulrich G. Steidl, MDPhD, Amit Verma, MD, Ira Braunschweig, MD, Ioannis Mantzaris, MD

Blood (2017) 130 (Supplement 1): 3293.

https://doi.org/10.1182/blood.V130.Suppl_1.3293.3293

Published: 2017

Journal Articles

North American Adult T Cell Leukemia Lymphoma (ATLL) Is Characterized By Distinct, Therapeutically Targetable Mutations in Epigenetic Modifiers

Blood (2017) 130 (Supplement 1): 1455.

https://doi.org/10.1182/blood.V130.Suppl_1.1455.1455

Published: 2017

Journal Articles

Barriers and Opportunities in Accrual of HIV-Positive Minority Underserved Patients with Non-Hodgkin Lymphoma, into AIDS Malignancy Consortium (AMC) Clinical Trials: A Retrospective 12- Year Single Institution Experience

Sakshi Jasra, MD, Ali Mustafa, Amara Gayathri Nandikolla, MD, Urvi A Shah, MD, Yifei Zhang, MD, Ioannis Mantzaris, MD, Aditi Shastri, MD, Adam F. Binder, MD, Ira Braunschweig, MD, Noah Kornblum, MD, Amit Verma, MD, David M. Aboulafia, MD, Murali Janakiram, MD

Blood (2017) 130 (Supplement 1): 4135.

https://doi.org/10.1182/blood.V130.Suppl_1.4135.4135

Published: 2017

NARROW

Open Label Single Arm Study to Assess the Implementation of Home Based Daratumumab Administration in Patients Being Treated for Multiple Myeloma

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Outcome of Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide - a Single Center Experience

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Perceptions of a Home Blood Transfusion Program Among Patients with Hematologic Malignancies Who Are Newly Diagnosed As Compared to Those with Relapsed/Refractory Disease

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Assessment of the Diagnostic Accuracy of Core Needle Biopsies in the Diagnosis of Lymphoma

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Retrospective Analysis of the Relationship between Time to Anti-Resorptive Therapy and Incidence of Skeletal Related Events in Patients with Multiple Myeloma

Vaccination Response after Autologous Stem Cell Transplantation

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Autologous Transplantation Is Associated with Better Outcomes Compared to Chemotherapy Alone in a Minority-Rich Non-High-Risk Acute Myeloid Leukemia Cohort

North American Adult T Cell Leukemia Lymphoma (ATLL) Is Characterized By Distinct, Therapeutically Targetable Mutations in Epigenetic Modifiers

Barriers and Opportunities in Accrual of HIV-Positive Minority Underserved Patients with Non-Hodgkin Lymphoma, into AIDS Malignancy Consortium (AMC) Clinical Trials: A Retrospective 12- Year Single Institution Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only